1. See, for example, C. Orenberg, DES: The Complete Story (New York: St. Martin’s Press, 1981); R. Klein and R. Rowland, “Women As Test Sites for Fertility Drugs: Clomiphene Citrate and Hormonal Cocktails,” Reproductive and Genetic Engineering. Journal of International Feminist Analysis, 1: 3 (1988): 251–73;
2. Harriet Simand, “138–188: Fitly Years of DES -Fifty Years Too Many,” in The Future of Human Reproduction, ed., C. Overall ( Toronto: The Women’s Press, 1989 ), pp. 95–104;
3. R. Rowland, Living Laboratories (Bloomington: Indiana University Press, 1992), p. 50 (hereafter cited as Rowland, Laboratories);
4. S. M. Fisher and R. J. Apfel, “Diethylstilbestrol and Infertility: The Past, the Present, and the Relevance for the Future,” in Technology and Infertility, eds., M. M. Seibel, A. A. Kiessling, J. Bernstein, and S. R. Levin ( New York: Springer-Verlag, 1993 ), pp. 413–423.
5. See, for example, J. Jarrel, J. Seidel, and P. Bigelow, “Adverse Health Effects of Drugs Used for Ovulation Induction,” in New Reproductive Technologies and the Health Care System. The Case for Evidence-Based Medicine,Royal Commission on New Reproductive Technologies (Ottawa, Canada: Canada Communications Group, 1993), pp. 453–549 (hereafter cited as J. Jarrel et al,Adverse Health Effects);